US 12,215,352 B2
Cell culture method for mesenchymal stem cells
Paul Simmons, Melbourne (AU); and Colby Suire, New York, NY (US)
Assigned to MESOBLAST INTERNATIONAL SARL, Meyrin (CH)
Filed by Mesoblast International Sarl, Meyrin (CH)
Filed on Mar. 21, 2023, as Appl. No. 18/124,346.
Application 18/124,346 is a continuation of application No. 16/599,271, filed on Oct. 11, 2019, granted, now 11,685,899.
Application 16/599,271 is a continuation of application No. 15/553,115, abandoned, previously published as PCT/EP2016/054640, filed on Mar. 4, 2016.
Claims priority of application No. 2015900752 (AU), filed on Mar. 4, 2015; and application No. 2015900777 (AU), filed on Mar. 5, 2015.
Prior Publication US 2024/0191200 A1, Jun. 13, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/077 (2010.01); C12N 5/0775 (2010.01)
CPC C12N 5/0662 (2013.01) [C12N 2500/99 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/135 (2013.01)] 10 Claims
 
1. A serum-free cell culture medium comprising:
a basal medium;
10 ng/ml or less of platelet derived growth factor-BB (PDGF-BB);
1 ng/ml or less of fibroblast growth factor 2 (FGF2); and 5 ng/ml or less of epidermal growth factor (EGF); and
mesenchymal lineage precursor cells in an undifferentiated state.